How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

3,153 results for

Migraine Headache Management

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Acupuncture for migraine headaches

Acupuncture for migraine headaches Acupuncture for migraine headaches Toggle navigation Shared more. Cited more. Safe forever. Toggle navigation View Item JavaScript is disabled for your browser. Some features of this site may not work without it. Search MOspace This Collection Browse Statistics Acupuncture for migraine headaches View/ Open Date 2010-04 Format Metadata Abstract Acupuncture reduces the frequency of migraine headaches when used as an adjunct to, or in place of, medical management

2019 Clinical Inquiries

2. Acupuncture for migraine headaches

Acupuncture for migraine headaches Acupuncture for migraine headaches Toggle navigation Shared more. Cited more. Safe forever. Toggle navigation View Item JavaScript is disabled for your browser. Some features of this site may not work without it. Search MOspace This Collection Browse Statistics Acupuncture for migraine headaches View/ Open Date 2010-04 Format Metadata Abstract Acupuncture reduces the frequency of migraine headaches when used as an adjunct to, or in place of, medical management

2019 Clinical Inquiries

3. Management of Childhood Migraine by Headache Specialist vs Non-Headache Specialists. (PubMed)

Management of Childhood Migraine by Headache Specialist vs Non-Headache Specialists. This study aims to compare the management practices of a headache specialist with non-headache specialists in the treatment of children with migraine. The use of appropriate rescue medications and prophylactic agents, application of neuroimaging, and short-term outcomes are compared in children treated by the two groups of physicians.A retrospective cohort study was conducted by utilizing the electronic medical (...) records of children 3-18 years of age with migraine, who were evaluated at a tertiary care children's hospital from 2016 to 2018.Of the 849 patients who met the study criteria, 469 children were classified as having chronic migraine or high-frequency episodic migraine and were followed-up on at least 1 occasion by the neurologists. Imaging was obtained in 66.5% of all children with migraine. The headache specialist used 5-HT agonists ("triptans") for migraine management in 56.7% (76/135) of cases

2019 Headache

4. Migraine and Tension Headache

Background This guideline includes diagnosis and treatment of the most common headache types that are managed in primary care: • Tension headacheMigraine headache, including menstrual migraine • Medication overuse headache (also known as rebound headache) Cluster headaches are excluded from this guideline because of their low prevalence in the general population and the severity of the symptoms. For patients with suspected cluster headaches, consider consulting with Neurology for evaluation (...) , Silberstein SD, Schwedt TJ. The Acute Treatment of Migraine in Adults: The American Headache Society Evidence Assessment of Migraine Pharmacotherapies. Headache. 2015;55:3-20. 2015 National Institute for Health and Care Excellence (NICE). Headaches in over 12s: diagnosis and management. Clinical guideline CG150. Last updated: November 2015. 14 Key question 1 What is the clinical effectiveness of antiemetics, aspirin, NSAIDs, opioids, triptans, ergots, and corticosteroids for acute treatment of migraine

2018 Kaiser Permanente Clinical Guidelines

5. The Traffic Light of Headache: Simplifying Acute Migraine Management for Physicians and Patients Using the Canadian Headache Society Guidelines. (PubMed)

The Traffic Light of Headache: Simplifying Acute Migraine Management for Physicians and Patients Using the Canadian Headache Society Guidelines. Migraine is a disabling neurological condition and it is well described that early treatment is more effective and less likely to lead to headache recurrence. While it would seem intuitive for a migraine sufferer to treat early, despite well-established guidelines by the Canadian Headache Society, many sufferers continue to treat late. As a result (...) , acute therapy is less effective, resulting in higher associated disability and a longer lasting attack. Pain scales can help patients determine how to treat; however, we propose a simple, easily recalled traffic light system to help patients determine which drug to use based upon how they feel. The traffic light system is based on the associated disability of the migraine attack, with green being a "I can still go" headache, a yellow being a "I have to slow down" headache, and a red being a "I have

2018 Headache

6. Monoclonal antibodies to prevent migraine headaches

to Adverse Events 0 1 (1) NoP= number of patients. Concurrent Developments PROMISE-2 is a phase III, randomized, double-blind, placebo- controlled trial of eptinezumab currently being conducted in the prevention of chronic migraines. The final data collection date for the primary outcomes measure (change in number of migraine days) is set for June 2018. 47 Galcanezumab and fremanezumab are currently in phase III trials for the management of cluster headaches. 48-53 Atogepant (AGN-241689, formerly MK-8031 (...) Monoclonal antibodies to prevent migraine headaches Monoclonal antibodies to prevent migraine headaches | CADTH.ca CADTH Document Viewer Monoclonal antibodies to prevent migraine headaches Table of Contents Search this document Monoclonal antibodies to prevent migraine headaches February 2018 Summary Migraine is a common, chronic, neurological disorder. To prevent chronic migraine headaches, botulinum toxin has received regulatory approval. This medication requires multiple injections

2018 CADTH - Issues in Emerging Health Technologies

7. Chronic migraine and chronic tension-type headache

is not a covered benefit. HTCC reimbursement determination: Limitations of coverage: For treatment of chronic migraine (as defined by the International Headache Society), OnabotulinumtoxinA is covered when the following criteria are met: 1) Has not responded to at least three prior pharmacological prophylaxis therapies from two different classes of drugs AND 2) Condition is appropriately managed for medication overuse OnabotulinumtoxinA injections must be discontinued when the condition has shown inadequate (...) with chronic migraine (defined as headaches on =15 days per month of which =8 days are with migraine) if: 1) They have not responded to at least three prior pharmacological prophylaxis therapies from two different classes of drugs AND 2) Their condition is appropriately managed for medication overuse OnabotulinumtoxinA injections must be discontinued in people whose condition: 1) Has shown inadequate response to treatment (defined as <50% reduction in headache days per month after two treatment cycles

2017 Washington Health Care Authority

8. Pain Management Using Acupuncture Method in Migraine Headache Patients; A Single Blinded Randomized Clinical Trial. (PubMed)

Pain Management Using Acupuncture Method in Migraine Headache Patients; A Single Blinded Randomized Clinical Trial. There were numerous studies using acupuncture for pain relief and in most, the effect of this technique on preventing migraine attacks has been investigated. In those several studies that surveyed the effect of acupuncture on treatment of migraine headaches, the conclusion was not completely persuaded and they suggested further researches on this topic.The purpose of this study (...) is to examine the effect of acupuncture on controlling acute migraine attacks.This study was a single blinded randomized clinical trial that was conducted on patients with a diagnosis of acute migraine attacks. At the time of reference, the patient's pain intensity was measured and recorded in a written checklist. Acupuncture was done in the intervention group with thin metallic needles, which enter certain points in the ear's skin; including shen men, autonomic, thalamus, frontal, and temple

Full Text available with Trip Pro

2018 Anesthesiology and pain medicine

9. Practice guideline update summary: Pharmacologic treatment for pediatric migraine prevention: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Headache Society

controlled trials studying the efficacy of preventive medications for pediatric migraine fail to demonstrate superiority to placebo. Recommendations for the prevention of migraine in children include counseling on lifestyle and behavioral factors that influence headache frequency and assessment and management of comorbid disorders associated with headache persistence. Clinicians should engage in shared decision-making with patients and caregivers regarding the use of preventive treatments for migraine (...) Practice guideline update summary: Pharmacologic treatment for pediatric migraine prevention: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Headache Society To provide updated evidence-based recommendations for migraine prevention using pharmacologic treatment with or without cognitive behavioral therapy in the pediatric population.The authors systematically reviewed literature from January 2003

Full Text available with Trip Pro

2019 EvidenceUpdates

10. Pharmacological management of migraine

for the purpose of implementation in NHSScotland. Pharmacological management of migraineContents 1 Introduction 1 1.1 The need for a guideline 1 1.2 Remit of the guideline 2 1.3 Statement of intent 3 2 Key recommendations 5 2.1 Acute treatment 5 2.2 Prevention of migraine 6 2.3 Medication-overuse headache 6 3 Treatment for patients with acute migraine 7 3.1 Introduction 7 3.2 Aspirin 7 3.3 Non-steroidal anti-inflammatory drugs 8 3.4 Paracetamol 8 3.5 Antiemetics 9 3.6 Triptans 9 3.7 Combined therapies 11 3.8 (...) 4.14 Occipital nerve block 19 4.15 Calcitonin gene-related peptide 19 4.16 Menstrual migraine prophylaxis 19 Pharmacological management of migraine Contents5 Medication-overuse headache 21 6 Devices for migraine therapy 23 6.1 Vagus nerve stimulation 23 6.2 Transcutaneous supraorbital nerve stimulation 23 6.3 Transcranial magnetic stimulation 23 7 Provision of information 24 7.1 Publications from SIGN 24 7.2 Sources of further information 24 7.3 Checklist for provision of information to patients 25

2018 SIGN

11. Critical Issues in the Evaluation and Management of Adult Patients Presenting to the Emergency Department With Acute Headache

regimens for migraine 370 headache. The results clearly demonstrated significant use of opioids in migraine management. Of the 1,222 visits 371 for migraine headaches, 35.8% had opioid medications ordered. Overall, opioid use was greatest in the community 372 setting in which it was ordered during 68.6% of visits. The urban ED used opioids for 40.9% of the migraine 373 patients, with 12.3% used in the academic medical center. Opioids were used a greater percentage as a rescue agent 374 (49.9% of visits (...) is an area that warrants clear guidelines related to clinical 384 13 treatment alternatives to opioid administration. Although there are a significant number of studies that look at the 385 acute management of headache, there are limited data that provide comparison data between opioid and nonopioid 386 treatment. This literature search looked across all different causes of headache; however, most of the studies 387 identified addressed migraine headache. This systematic review identified a total of 3

2019 American College of Emergency Physicians

12. A Systematic Review of Atypical Antipsychotics in Chronic Pain Management: Olanzapine Demonstrates Potential in Central Sensitization, Fibromyalgia, and Headache/Migraine. (PubMed)

A Systematic Review of Atypical Antipsychotics in Chronic Pain Management: Olanzapine Demonstrates Potential in Central Sensitization, Fibromyalgia, and Headache/Migraine. Many psychopharmacologic agents are used as primary or adjuncts in pain management. Atypical antipsychotics (AAs) have also been used as adjuncts in pain management regimens in a variety of manners; however, their efficacy in this capacity is unclear.A systematic review of all studies examining AA use for pain was conducted (...) , risperidone, aripiprazole, and ziprasidone are the only AAs with published studies in pain management. Among these, olanzapine and quetiapine have the most studies (11 and 6, respectively). Olanzapine shows preliminary and consistent efficacy in fibromyalgia and headache/migraine, although only 1 study was a randomized controlled trial with level I evidence of efficacy. Other AAs eg, (quetiapine) fail to demonstrate efficacy in pain syndromes and/or lack robust study designs.Few studies have been

2017 The Clinical Journal of Pain

13. Non-pharmacological self-management for people living with migraine or tension-type headache: a systematic review including analysis of intervention components. (PubMed)

Non-pharmacological self-management for people living with migraine or tension-type headache: a systematic review including analysis of intervention components. To assess the effect of non-pharmacological self-management interventions against usual care, and to explore different components and delivery methods within those interventions PARTICIPANTS: People living with migraine and/or tension-type headache INTERVENTIONS: Non-pharmacological educational or psychological self-management (...) (-0.82 to -0.18) vs 0.34 (-0.44 to -0.24)) and in interventions delivered in groups vs one-to-one delivery (0.56 (-0.72 to -0.40) vs -0.39 (-0.52 to -0.27)) and larger effects on mood in interventions including a cognitive-behavioural therapy (CBT) component with an SMD of -0.72 (-0.93 to -0.51) compared with those without CBT -0.41 (-0.58 to -0.24).Overall we found that self-management interventions for migraine and tension-type headache are more effective than usual care in reducing pain intensity

Full Text available with Trip Pro

2017 BMJ open

14. Comparing Zonisamide With Sodium Valproate in the Management of Migraine Headaches: Double-Blind Randomized Clinical Trial of Efficacy and Safety. (PubMed)

Comparing Zonisamide With Sodium Valproate in the Management of Migraine Headaches: Double-Blind Randomized Clinical Trial of Efficacy and Safety. Migraine is one of the most debilitating medical conditions and has a high socioeconomic burden. As conventional therapeutic methods do not entirely alleviate the symptoms, new alternatives are being considered.This study evaluates the efficacy and safety of zonisamide compared with sodium valproate in the management of migraine headaches.In (...) the current double-blind, parallel, randomized, controlled trial, 96 patients with a migraine diagnosis based on the international headache society (HIS) criteria were selected. They were divided randomly into two groups; the case group was given zonisamide, and sodium valproate was given to a control group. In addition to the side effects of the drugs, the severity, duration, and frequency of migraine attacks were evaluated at baseline and at three months.The 96 selected patients were divided randomly

Full Text available with Trip Pro

2017 Iranian Red Crescent medical journal

15. Lifting the burden of headache in China: managing migraine in a SMART way (PubMed)

Lifting the burden of headache in China: managing migraine in a SMART way With support from Lifting The Burden , a UK-registered charitable organization, a nationwide survey of headache disorders in the Chinese adult population was conducted in 2008-2009. This project, which was within the Global Campaign against Headache, showed that headache disorders have a major adverse impact on public health in China. Subsequently, as essential support for implementing headache services around the country (...) , an enactment of stage 3 (intervention) of the Global Campaign against Headache - the continuing medical education (CME) program Headache Schools - was established. 'SMART' (Screen, Migraine, Aura, Red flag and Treatment), a systematic and operational disease management model, was introduced with the aims of enhancing neurologists' knowledge of migraine, standardizing their diagnostic and treatment approaches, and improving their practices and outcomes. To date, 615 neurologists have been trained and 135

Full Text available with Trip Pro

2017 The journal of headache and pain

16. Ketorolac versus Magnesium Sulfate in Migraine Headache Pain Management; a Preliminary Study (PubMed)

Ketorolac versus Magnesium Sulfate in Migraine Headache Pain Management; a Preliminary Study Migraine is a common cause of emergency department (ED) visits. To date, there is no recommended drug of choice for pain management of these patients. In the present study, we aimed to evaluate the effectiveness of ketorolac and magnesium sulfate in this regard.This is a cross-sectional study performed on all 18 - 60 year-old patients, visiting two different EDs with complaint of moderate to severe (...) migraine headache. Patients were treated with 30 mg ketorolac in one hospital and 1 gram magnesium sulfate in the other. Pain scores were assessed on arrival, 1 and 2 hours after drugs administration and quality of pain management was compared between two groups using SPSS 22.70 patients with the mean age of 36.4 ± 11.4 years were enrolled (51.4% male). The two groups were similar regarding baseline characteristics (p > 0.05). The improvement in pain score in magnesium sulfate group was greater than

Full Text available with Trip Pro

2017 Emergency

17. Onabotulinumtoxin A for the management of chronic migraine in current clinical practice: results of a survey of sixty-three Italian headache centers (PubMed)

Onabotulinumtoxin A for the management of chronic migraine in current clinical practice: results of a survey of sixty-three Italian headache centers Chronic migraine is a complex clinical condition often undertreated. Onabotulinumtoxin A (OBT-A) was approved in Italy in 2013 for symptom relief in patients with chronic migraine who have failed, or do not tolerate, oral prophylactic treatments. However, the impact of OBT-A in clinical practice remains to be defined.To investigate the current (...) management of chronic migraine with OBT-A in clinical practice, a web-based survey was conducted among clinicians working in third-level headache centers across Italy. A 26-item questionnaire was designed and developed by a group of 10 Italian headache specialists to address the following issues: treatment paradigm and OBT-A injection intervals, frequency of treatment and retreatment, definition of responders/non-responders, satisfaction with treatment potential impact of early treatment with OBT

Full Text available with Trip Pro

2017 The journal of headache and pain

18. Migraine and Other Headache Disorders: ACOG Clinical Updates In Women's Health Care Primary and Preventive Care Review Summary Volume XVIII, Number 4. (PubMed)

and possible medication change may be necessary. Women also have unique risks for secondary headache during pregnancy, particularly pregnant women with a history of migraine. Therefore, a large portion of this monograph is devoted to evaluation, management, and drug safety in pregnant or breastfeeding women. (...) Migraine and Other Headache Disorders: ACOG Clinical Updates In Women's Health Care Primary and Preventive Care Review Summary Volume XVIII, Number 4. Migraine is a common headache disorder for which women are likely to seek care. This primary headache disorder, which often may be debilitating, has a higher prevalence in women than in men that is likely related to times of hormonal changes throughout the reproductive life cycle, such as menarche, pregnancy, postpartum period, lactation

2019 Obstetrics and Gynecology

19. Targeting CGRP for the Prevention of Migraine and Cluster Headache: A Narrative Review. (PubMed)

Targeting CGRP for the Prevention of Migraine and Cluster Headache: A Narrative Review. Calcitonin-gene-related peptide (CGRP), a neuropeptide broadly distributed in neuronal and non-neuronal regions throughout the body, plays a fundamental role in migraine and cluster headache (CH) pathophysiology. CGRP functional blockade alleviates neurogenic inflammation and reduces pain pathway sensitization. Two types of CGRP function-blocking modalities, monoclonal antibodies (MAbs), and small molecules (...) (gepants), have been designed to target the CGRP ligands and CGRP receptors. In this narrative review, we summarized the latest clinical trials on gepants and CGRP function-blocking MAbs for migraine and CH prevention. At the time of writing, newer gepants are currently under Federal Drug Administration (FDA) review for migraine management, but there is no study yet on the usage of gepants for CH. Erenumab, fremanezumab, and galcanezumab have been approved by the FDA for migraine prevention while

2019 Headache

20. Practice guideline update summary: Pharmacologic treatment for pediatric migraine prevention: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Headache Society. (PubMed)

of randomized controlled trials studying the efficacy of preventive medications for pediatric migraine fail to demonstrate superiority to placebo. Recommendations for the prevention of migraine in children include counseling on lifestyle and behavioral factors that influence headache frequency, and assessment and management of comorbid disorders associated with headache persistence. Clinicians should engage in shared decision making with patients and caregivers regarding the use of preventive treatments (...) Practice guideline update summary: Pharmacologic treatment for pediatric migraine prevention: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Headache Society. To provide updated evidence-based recommendations for migraine prevention using pharmacologic treatment with or without cognitive behavioral therapy in the pediatric population.The authors systematically reviewed literature from January 2003

2019 Headache

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>